相似文献
1
Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis.
Autoimmun Rev. 2011 Apr;10(6):331-5. doi: 10.1016/j.autrev.2010.12.002. Epub 2010 Dec 15.
2
Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis.
Autoimmun Rev. 2013 Oct;12(12):1123-8. doi: 10.1016/j.autrev.2013.06.015. Epub 2013 Jun 24.
3
Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer.
Scand J Immunol. 2009 Jan;69(1):57-63. doi: 10.1111/j.1365-3083.2008.02195.x.
4
Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma.
Dis Esophagus. 2014 Nov-Dec;27(8):790-7. doi: 10.1111/dote.12145. Epub 2013 Oct 21.
5
Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
Prostate. 2005 May 15;63(3):252-8. doi: 10.1002/pros.20181.
6
Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of esophageal cancer.
Asian Pac J Cancer Prev. 2014;15(6):2635-40. doi: 10.7314/apjcp.2014.15.6.2635.
7
Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis.
Tumour Biol. 2014 Mar;35(3):2661-7. doi: 10.1007/s13277-013-1350-6. Epub 2014 Jan 8.
8
Autoantibodies to tumor-associated antigens: reporters from the immune system.
Immunol Rev. 2008 Apr;222:328-40. doi: 10.1111/j.1600-065X.2008.00611.x.
9
Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer.
Scand J Immunol. 2012 Mar;75(3):342-9. doi: 10.1111/j.1365-3083.2011.02657.x.
10
Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
J Cell Biochem. 2019 Mar;120(3):3091-3100. doi: 10.1002/jcb.27497. Epub 2018 Nov 28.
引用本文的文献
1
Screening colorectal cancer associated autoantigens through multi-omics analysis and diagnostic performance evaluation of corresponding autoantibodies.
BMC Cancer. 2025 Apr 16;25(1):713. doi: 10.1186/s12885-025-14080-5.
2
Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.
Front Immunol. 2024 Aug 21;15:1455602. doi: 10.3389/fimmu.2024.1455602. eCollection 2024.
3
Anti-BIRC5 autoantibody serves as a valuable biomarker for diagnosing AFP-negative hepatocellular carcinoma.
PeerJ. 2024 May 31;12:e17494. doi: 10.7717/peerj.17494. eCollection 2024.
4
Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
Sci Rep. 2024 Apr 29;14(1):9757. doi: 10.1038/s41598-024-60544-2.
5
A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma.
Cancer Cell Int. 2023 Nov 16;23(1):273. doi: 10.1186/s12935-023-03107-1.
6
Identification of novel serum autoantibody biomarkers for early esophageal squamous cell carcinoma and high-grade intraepithelial neoplasia detection.
Front Oncol. 2023 May 12;13:1161489. doi: 10.3389/fonc.2023.1161489. eCollection 2023.
7
From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer.
Front Genet. 2023 Feb 24;14:1110656. doi: 10.3389/fgene.2023.1110656. eCollection 2023.
8
A Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity.
Front Oncol. 2022 Jun 16;12:888556. doi: 10.3389/fonc.2022.888556. eCollection 2022.
9
Identification and validation of serum autoantibodies in children with B-cell acute lymphoblastic leukemia by serological proteome analysis.
Proteome Sci. 2022 Feb 2;20(1):3. doi: 10.1186/s12953-021-00184-w.
10
Tumor-Associated Antigens (TAAs) for the Serological Diagnosis of Osteosarcoma.
Front Immunol. 2021 Apr 30;12:665106. doi: 10.3389/fimmu.2021.665106. eCollection 2021.
本文引用的文献
1
CIP2A is associated with human breast cancer aggressivity.
Clin Cancer Res. 2009 Aug 15;15(16):5092-100. doi: 10.1158/1078-0432.CCR-08-3283. Epub 2009 Aug 11.
2
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. doi: 10.1093/jnci/djp103. Epub 2009 May 26.
3
A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation.
J Pathol. 2008 Aug;215(4):445-56. doi: 10.1002/path.2376.
4
Autoantibodies to tumor-associated antigens: reporters from the immune system.
Immunol Rev. 2008 Apr;222:328-40. doi: 10.1111/j.1600-065X.2008.00611.x.
5
CIP2A inhibits PP2A in human malignancies.
Cell. 2007 Jul 13;130(1):51-62. doi: 10.1016/j.cell.2007.04.044.
6
Involvement of PP2A in viral and cellular transformation.
Oncogene. 2005 Nov 21;24(52):7746-55. doi: 10.1038/sj.onc.1209038.
7
The sentinel within: exploiting the immune system for cancer biomarkers.
J Proteome Res. 2005 Jul-Aug;4(4):1123-33. doi: 10.1021/pr0500814.
8
PP2A: the expected tumor suppressor.
Curr Opin Genet Dev. 2005 Feb;15(1):34-41. doi: 10.1016/j.gde.2004.12.004.
9
Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
Prostate. 2005 May 15;63(3):252-8. doi: 10.1002/pros.20181.
10
Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis.
Prostate. 2005 Jan 1;62(1):14-26. doi: 10.1002/pros.20112.
Zotero 插件